Citigroup’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$53.3M Buy
348,789
+277,455
+389% +$42.5M 0.02% 624
2025
Q4
$9.83M Sell
71,334
-159,953
-69% -$20.9M ﹤0.01% 1546
2025
Q3
$29.7M Buy
231,287
+17,266
+8% +$2.11M 0.01% 860
2025
Q2
$25.9M Sell
214,021
-23,338
-10% -$2.63M 0.01% 844
2025
Q1
$26.5M Buy
237,359
+21,023
+10% +$2.24M 0.01% 829
2024
Q4
$21.1M Sell
216,336
-77,842
-26% -$8.3M 0.01% 930
2024
Q3
$33.8M Buy
294,178
+42,642
+17% +$4.84M 0.02% 695
2024
Q2
$26.8M Sell
251,536
-664,628
-73% -$66.7M 0.02% 764
2024
Q1
$88.6M Buy
916,164
+676,034
+282% +$69.3M 0.06% 304
2023
Q4
$24.2M Buy
240,130
+55,429
+30% +$5.35M 0.02% 757
2023
Q3
$18.8M Buy
184,701
+725
+0.4% +$73.6K 0.01% 797
2023
Q2
$18.6M Sell
183,976
-111,575
-38% -$11.2M 0.01% 858
2023
Q1
$27.2M Buy
295,551
+119,005
+67% +$10.4M 0.02% 663
2022
Q4
$16M Buy
176,546
+8,415
+5% +$709K 0.01% 894
2022
Q3
$12.8M Buy
168,131
+1,420
+0.9% +$118K 0.01% 1017
2022
Q2
$14.1M Buy
166,711
+245
+0.1% +$21.5K 0.01% 971
2022
Q1
$14.6M Buy
166,466
+12,745
+8% +$1.1M 0.01% 1103
2021
Q4
$13.4M Sell
153,721
-42,016
-21% -$3.49M 0.01% 1218
2021
Q3
$16M Sell
195,737
-90,610
-32% -$8.15M 0.01% 1134
2021
Q2
$26.1M Buy
286,347
+10,830
+4% +$964K 0.02% 846
2021
Q1
$23.6M Buy
275,517
+46,968
+21% +$4.21M 0.02% 870
2020
Q4
$21.6M Buy
228,549
+8,485
+4% +$741K 0.01% 988
2020
Q3
$19.1M Buy
220,064
+521
+0.2% +$45.1K 0.01% 925
2020
Q2
$19.2M Sell
219,543
-30,405
-12% -$2.62M 0.02% 852
2020
Q1
$20.6M Buy
249,948
+11,950
+5% +$1.07M 0.02% 716
2019
Q4
$22.5M Buy
237,998
+83,986
+55% +$7.54M 0.02% 899
2019
Q3
$13.4M Sell
154,012
-131,815
-46% -$11.8M 0.01% 1186
2019
Q2
$26.1M Buy
285,827
+16,207
+6% +$1.37M 0.02% 785
2019
Q1
$23.2M Buy
269,620
+129,389
+92% +$10.4M 0.02% 746
2018
Q4
$10.8M Sell
140,231
-195
-0.1% -$15.2K 0.01% 1206
2018
Q3
$10.8M Buy
140,426
+7,776
+6% +$575K 0.01% 1231
2018
Q2
$8.98M Sell
132,650
-62,345
-32% -$4.3M 0.01% 1366
2018
Q1
$14.2M Buy
194,995
+46,921
+32% +$3.57M 0.01% 1005
2017
Q4
$11.1M Sell
148,074
-27,998
-16% -$2.11M 0.01% 1214
2017
Q3
$13.5M Buy
176,072
+37,419
+27% +$2.83M 0.01% 1027
2017
Q2
$10.4M Buy
138,653
+26,641
+24% +$1.89M 0.01% 1120
2017
Q1
$7.45M Sell
112,012
-70,105
-38% -$4.67M 0.01% 1351
2016
Q4
$11.9M Buy
182,117
+35,956
+25% +$2.33M 0.01% 1073
2016
Q3
$10.3M Sell
146,161
-29,476
-17% -$2.15M 0.01% 1061
2016
Q2
$13M Sell
175,637
-6,330
-3% -$437K 0.01% 871
2016
Q1
$11.8M Sell
181,967
-4,669
-3% -$318K 0.01% 889
2015
Q4
$14.4M Buy
186,636
+31,663
+20% +$2.52M 0.01% 915
2015
Q3
$12.8M Buy
154,973
+49,539
+47% +$4.41M 0.01% 985
2015
Q2
$9.29M Buy
105,434
+6,521
+7% +$598K 0.01% 1253
2015
Q1
$8.74M Sell
98,913
-102,779
-51% -$9.12M 0.01% 1280
2014
Q4
$16.7M Sell
201,692
-26,421
-12% -$2.19M 0.02% 906
2014
Q3
$19.2M Buy
228,113
+6,898
+3% +$558K 0.02% 832
2014
Q2
$17.9M Buy
221,215
+43,768
+25% +$3.44M 0.02% 859
2014
Q1
$13.5M Buy
177,447
+30,555
+21% +$2.23M 0.01% 963
2013
Q4
$10.6M Buy
146,892
+7,596
+5% +$528K 0.01% 1195
2013
Q3
$9.57M Buy
139,296
+13,615
+11% +$901K 0.01% 1204
2013
Q2
$7.96M Buy
+125,681
New +$8.18M 0.01% 1249

Other funds holding NVS

Citigroup's NVS Position: Q1 2026 in Review

Citigroup increased its Novartis (NVS) stake by 389% in Q1 2026, buying an estimated $42.5M and bringing the position to 348,789 shares worth $53.3M. The position accounts for 0.02% of the portfolio, ranked #624.

Citigroup first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.6M in Q1 2024. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Citigroup held 348,789 shares of Novartis worth $53.3M as of Q1 2026.
  • Citigroup bought 277,455 Novartis shares in Q1 2026, an estimated $42.5M.
  • Novartis made up 0.02% of Citigroup's portfolio in Q1 2026, its #624 holding.
  • Citigroup first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Novartis position peaked at $88.6M in Q1 2024.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.